Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition
Martínez, Clara Mª
Gimenez, Mª Teresa
Fernández de Larrea, Carlos
GEMMAC (Grup per l’estudi del mieloma i l’amiloïdosi de Catalunya)
MetadataShow full item record
The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1–4%, 5–20%, and plasma cell leukemia with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and 5 (1.0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4.9, 95% CI 2.6–9.3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with ≥5% circulating plasma cells had lower platelet counts (median 86×109/L vs. 214×109/L, P<0.0001) and higher bone marrow plasma cells (median 53% vs. 36%, P=0.004). The presence of ≥5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia.
Is part ofHaematologica, 2017, vol. 102, núm. 6, p. 1099-1104
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by-nc (c) Ferrata Storti Foundation, 2017
Showing items related by title, author, creator and subject.
Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome Sánchez Castro, Judit; Marco Betés, Victor; Gómez Arbonés, Javier; Arenillas, Leonor; Valcarcel, David; Vallespí, Teresa; Costa, Dolors; Nomdedeu, Benet; Jimenez, María José; Granada, Isabel; Grau, Javier; Ardanaz, María T.; Serna, Javier de la; Carbonell, Félix; Cervera, José; Sierra, Adriana; Luño, Elisa; Cervero, Carlos J.; Falantes, José; Calasanz, María J.; González-Porrás, José R.; Bailén, Alicia; Amigo, M. Luz; Sanz, Guillermo; Solé, Francesc (Elsevier, 2013)The prognosis of chromosome 17 (chr17) abnormalities in patients with primary myelodysplastic syndrome (MDS) remains unclear. The revised International Prognostic Scoring System (IPSS-R) includes these abnormalities within ...
Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity Pavón, Francisco Javier; Araos, Pedro; Pastor, Antoni; Calado, Montserrat; Pedraz, María; Campos Cloute, Rafael; Ruiz, Juan Jesús; Serrano, Antonia; Blanco Calvo, Eduardo; Rivera, Patricia; Suárez, Juan; Romero-Cuevas, Miguel; Pujadas, Mitona; Vergara-Moragues, Esperanza; Gornemann, Isolde; Torrens, Marta; De la Torre, Rafael; Rodríguez de Fonseca, Fernando (John Wiley & Sons, 2013-11-14)Cocaine is associated with serious health problems including psychiatric co-morbidity. There is a need for the identification of biomarkers for the stratification of cocaine-addicted subjects. Several studies have evaluated ...
Inflammatory response of ischemic tolerance in circulating Plasma: preconditioning-Induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS) Colàs Campàs, Laura; Farré, Joan; Mauri-Capdevila, Gerard; Molina Seguin, Jessica; Aymerich, Núria; Ois, Ángel; Roquer, Jaume; Tur, Silvia; García-Carreira, María del Carmen; Martí-Fàbregas, Joan; Cruz-Culebras, Antonio; Segura, Tomás; Arque, Gloria; Purroy Garcia, Francisco (Frontiers Media, 2020)